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ABSTRACT: Surfactant–liposome interactions have historically been investigated as a simplified model of solubilization and breakdown of
biological membranes by surfactants. In contrast, our goal was to utilize surfactants to modify the encapsulation and release properties of
liposomes. The ability to manufacture one liposomal formulation, which could be modified by the addition of a surfactant to support a wide
range of release profiles, would provide greater flexibility than manufacturing multiple batches of liposomes, each differing in composition
and with its own specific release profile. A liposomal ciprofloxacin formulation was modified by the addition of various surfactants.
These formulations were characterized in terms of liposome structure by cryo-TEM imaging, vesicle size by dynamic light scattering,
drug encapsulation by centrifugation–filtration, and in vitro release (IVR) performance. The addition of polysorbate 20 or polysorbate
80 to liposomal ciprofloxacin, in a hypotonic environment, resulted in a concentration-dependent loss of encapsulated drug, and above
0.4% polysorbate 20, or 0.2% polysorbate 80, a modified IVR profile as well. This study demonstrates that the encapsulation and release
properties of a liposomal formulation can be modified postmanufacture by the addition of judiciously chosen surfactants in combination
with osmotic swelling of the liposomes and may support a personalized approach to treating patients. C© 2014 Wiley Periodicals, Inc. and
the American Pharmacists Association J Pharm Sci 103:1851–1862, 2014
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INTRODUCTION
There are a range of formulation technologies that can be used
to modulate the release properties of pharmaceutical drugs, in-
cluding liposomes.1 Liposomes are phospholipid vesicles com-
posed of one or more lipid bilayers surrounding an aqueous
core and can vary in size ranging from approximately 20 nm to
10 :m.2 Liposomes as drug delivery vehicles are now well ac-
cepted with more than 10 approved liposomal products on the
market.3 A wide variety of drugs have been formulated into li-
posomes including small molecules, peptides, and nucleic acids;
hydrophilic drugs are generally dissolved in the aqueous com-
partment, whereas hydrophobic drugs are associated with the
lipid bilayers.1,2 The liposome composition, lamellarity, and the
manufacturing process can each influence the physicochemical
properties of a liposomal product, including its drug release ki-
netics. Although there are a wide number of variables in play
to produce liposomal formulations with differing pharmacoki-
netics, it would be complex and costly to market multiple lipo-
somal compositions to cover a broad range of release profiles. A
liposomal formulation which could be easily modified postman-
ufacture to produce different release profiles has the potential
to provide greater flexibility in treatment.
Abbreviations used: CF, carboxyfluorescein; CFI, ciprofloxacin for inhalation;
Cryo-TEM, cryogenic transmission electron microscopy; DLS, dynamic light
scattering; DRCFI, dual release ciprofloxacin for inhalation; IVR, in vitro
release; PC, phosphatidylcholine; TEA, triethylamine.
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In the present study, we were interested whether the release
properties of a liposomal ciprofloxacin for inhalation (CFI) could
be modified by the addition of a surfactant to the drug product
postmanufacture. One could envision a scenario in which this
simple procedure is performed by a doctor or a patient, from
a kit containing ampules with different concentrations of sur-
factant, or different surfactants, to provide a formulation tai-
lored to the specific needs of that patient. This could prove less
costly, and less complex, than developing and manufacturing
multiple, unique liposomal formulations which differ in compo-
sition to cover a broad range of release profiles. However, to our
knowledge, this represents a new paradigm as surfactant has
not previously been reported to be useful in the context of mod-
ifying the release properties of a liposome formulation, once it
has been manufactured. Of course, under this new personal-
ized medicine approach, new hurdles will arise such as how to
identify the appropriate release profile for each individual, but
that is not the focus of this paper.
There is an extensive history of detergents or surfactants
being used to solubilize biological membranes to allow for elu-
cidation of membrane structure and function.4 The ability of
surfactants to solubilize phospholipids, specifically, has been
reviewed.5 As surfactant is added to phospholipids, surfactant
initially partitions between the solution and the phospholipid
bilayers and the bilayer permeability may increase without loss
of structure.5 Once the phospholipid bilayers become saturated
with surfactant, the addition of more surfactant leads to the
formation of mixed micelles of surfactant and phospholipid un-
til all of the remaining surfactant-saturated bilayers are con-
verted to mixed micelles. Any further addition of surfactant
leads to a decrease in the size of the micelles as they become
Cipolla et al., JOURNAL OF PHARMACEUTICAL SCIENCES 103:1851–1862, 2014 1851
1852 RESEARCH ARTICLE – Pharmaceutical Nanotechnology
more dilute in phospholipid content. Vesicle–surfactant sys-
tems have frequently been characterized by monitoring their
light scattering properties, with maximum turbidity generally
associatedwith the surfactant-saturated bilayer state6 followed
by a rapid decline in turbidity once the bilayers are completely
solubilized by surfactant.7–12
Liposomes have also been used as a simplified model of bi-
ological membranes. Interest in the development of antimicro-
bials that would function by disruption of the bacterial mem-
brane spurred a better understanding of the interaction of
surfactant-like molecules with liposomes.13,14 During this same
time period, liposomes were also being investigated as drug de-
livery vehicles in their own right, so knowledge of the factors
which affected the timing and rate of release of the encapsu-
lated drug, including interaction with biological fluids, was im-
portant. After in vivo administration, liposomes come into con-
tact with many natural amphiphiles present in physiological
fluids. Surfactants were used as a simplification to the complex
biological milieu, allowing for characterization of drug release
from liposomes in the presence of surfactant.15
The observation that surfactants can interact with liposomes
to cause leakage of encapsulated drug was extensively investi-
gated in the 1970s and 1980s, but new insights into the mecha-
nism of surfactant-induced liposomal breakdown and the ki-
netics of release of the entrapped agent [carboxyfluorescein
(CF)] were just recently described.6 Upon the addition of sol-
ubilizing levels of surfactant, there is a complete breakdown
of liposome structure because of the direct interactions of the
surfactant molecules with the lipids, resulting in complete re-
lease of encapsulated drug in less than a second.6 At lower sur-
factant concentrations, surfactant molecules can cooperatively
assemble into structures which form pores in the liposomes,
again allowing for almost instantaneous release of a portion
of the encapsulated agent, but these holes then close limit-
ing further release.6 Nagawa and Regen13 demonstrated that
for some combinations of liposomes and surfactant, the encap-
sulated agent was released from all vesicles with increasing
surfactant concentration. For other combinations, there was a
catastrophic rupture inwhich a subset of the vesicles rapidly re-
leased their entire encapsulated payload, whereas others were
unaffected.13 Although there are many reports of loss of drug
from liposomes in response to surfactant addition, none have
shown that the surfactant can be used to modify the pharma-
cokinetic properties and thus the in vitro release (IVR) profile
of the liposomes.6,13–17
A mechanistic understanding of the interactions of surfac-
tants with liposomes is generally well understood; however, in-
terest in utilizing surfactants to modify the release properties
of liposomes for therapeutic purposes, which is the focus of this
paper, has not been explored. Rather than using the strongly
solubilizing surfactants, like TritonX-100, we chose surfactants
that are common to many pharmaceutical formulations, for
example, the polysorbates, to generate liposomal formulations
withmodified release properties.We also studied other nonionic
surfactants including poloxamers and spans, which are closely
related structurally to the polysorbates. It was expected that
these “milder” surfactants may not be sufficiently disruptive to
the liposomes at low concentrations to yield formulations with
significantly modified properties. To overcome this challenge,
we evaluated the combination of addition of surfactant along
with dilution of the liposomal formulations with water, to pro-
duce a hypotonic environment. The resulting osmotic swelling
of the liposomes might enhance the ability of the surfactant to
intercalate or associate with the liposome membrane and thus
alter its drug encapsulation and release properties. This paper
describes liposomal formulations of ciprofloxacin with modified
encapsulation and release properties because of the addition
of surfactant under hypotonic conditions. In line with the goal
of personalized medicine, to tailor a product to an individual’s
needs so that it releases the “right amount of drug at the right
time,” this strategy may provide more flexibility than the alter-
native of manufacturingmultiple batches of liposomes differing
in composition to cover a broad range of desired release profiles.
MATERIALS AND METHODS
Materials
Free ciprofloxacin (FCI), 20mg/mL in an acetate-buffered aque-
ous formulation at pH 3.3 and CFI, 50 mg/mL in a histidine-
buffered aqueous formulation at pH 6.0 were from Aradigm
Corporation (Hayward, California). (The ciprofloxacin concen-
trations are expressed in terms of ciprofloxacin hydrochloride.)
Polysorbate 20 was purchased from VWR Int. (West Chester,
New Jersey). Polysorbate 80, sorbitan monolaurate (Sp20), sor-
bitan monooleate (Sp80), poloxamer L44, and poloxamer L62
were a gift from Croda, Inc. (Edison, New Jersey). HEPES, free
acid was purchased from Avantor (Center Valley, Pennsylva-
nia). Sodium chloride was obtained fromAmresco (Solon, Ohio).
Sodium acetate was purchased from Sigma–Aldrich (St. Louis,
Missouri). HPLC grade methanol was purchased from Fisher
Scientific (Fair Lawn, New Jersey) and triethylamine (TEA)
was purchased from JT Baker (Center Valley, Pennsylvania).
Donor adult bovine serum was obtained from HyClone (Logan,
Utah). Nanosep centrifugal filtration devices, 10 K and 30 K
Damolecularweight, were obtained fromPall Corporation (Ann
Arbor, Michigan). Deionized water was used for all studies.
Preparation of Liposomal Ciprofloxacin
Ciprofloxacin for inhalation is an aqueous dispersion of unil-
amellar liposomes of approximately 80 nm containing hydro-
genated soy phosphatidylchocline (PC) and cholesterol. The
preparation of CFI has been reported previously.18 Briefly, mul-
tilamellar liposomes are extruded through membranes to pro-
duce unilamellar liposomes which are then actively loaded with
ciprofloxacin.19,20 Any unencapsulated ciprofloxacin is removed
by diafiltration resulting in >99% encapsulated ciprofloxacin
at a target concentration of 50 mg/mL. Dual-release CFI (DR-
CFI) is an equivolume mixture of FCI and CFI resulting in
approximately 70% encapsulated and approximately 30% FCI.
Addition of Surfactant to CFI
In the first series of experiments, CFI was diluted from
50 mg/mL to 30, 20, 15, 12.5, or 10 mg/mL with histidine buffer
(HB: 25 mM histidine, 145 mM sodium chloride buffer, pH 6.0)
and polysorbate 20 to achieve a final polysorbate 20 concentra-
tion of 0.1%, 0.2%, 0.4%, 0.8%, 1.2%, 1.6%, or 2.0% (w/v). A sec-
ond series of experiments was identical to the first except that
the CFI was diluted with water, instead of HB, to determine
whether osmotic swelling might play a role in enhancing the
effect of the addition of surfactant. In a third experiment, the
order of dilution was varied to determine whether the proper-
ties of these preparations depended upon the order of addition
of water and surfactant to the 12.5 mg/mL CFI preparations. In
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a fourth experiment, after 30 min equilibration, the 30 mg/mL
CFI preparations containing various levels of surfactant were
diluted with water to 10 mg/mL CFI to determine whether the
final encapsulation state was dependent upon the timing of the
preparation steps. In all of these experiments, the encapsula-
tion state was expressed as the mean of duplicate values.
Another series of experiments explored the use of various
surfactants, including Sp20, Sp80, poloxamer L62, poloxamer
L44, and polysorbate 80, to modify the properties of liposomal
ciprofloxacin, CFI. In these studies, the formulations contained
12.5 mg/mL CFI (i.e., diluted fourfold with water to produce
a hypotonic environment) in 0.01%, 0.05%, 0.1%, 0.5%, or 1%
(w/v) of each surfactant. A final experiment evaluated the re-
producibility of this effect across three different batches of CFI,
upon the addition of polysorbate 20 in a hypotonic environment.
In this study, 50 mg/mL CFI was diluted fourfold with water,
and 1% polysorbate 80 to a final concentration of 12.5 mg/mL
CFI in 0%, 0.05%, 0.1%, 0.2%, 0.3%, 0.4,% 0.5%, or 0.6% (w/v)
polysorbate 80.
In all experiments, the CFI samples containing surfactant
were allowed to equilibrate for at least 30 min to provide ade-
quate time for the surfactant to associate with the liposomes.
No further change in the properties of these formulations was
observed when samples were equilibrated for longer periods
of time (data not shown). For each of these preparations, the
vesicle size distribution and drug encapsulation states were
determined. For a number of the polysorbate 20 preparations,
cryogenic transmission electron microscopy (cryo-TEM) images
and IVR profiles were also obtained.
Vesicle Size
Each CFI or CFI plus surfactant sample was diluted with iso-
tonic saline to a concentration of approximately 1 mg/mL CFI
(2 mg/mL liposomes), and 0.5 mL was transferred to a dispos-
able culture tube (Kimble Glass Inc. (Vineland, NJ)) for vesi-
cle size analysis using a Submicron Particle Sizer Autodilute
Model 370 (Nicomp (Santa Barbara, CA)). The following in-
strument parameters were selected: temperature: 23◦C; viscos-
ity: 0.933; refractive index: 1.333; intensity set point: 300 kHz;
channel width: 10 :s; scattering angle: 90; run time: 5 min;
mode: vesicle; Gaussian distribution. The mean and SD of the
vesicle size distribution were recorded.
Drug Encapsulation
Nanosep Omega centrifugation devices (Pall Corporation) with
modified polyethersulfone membrane filters of 10,000 or 30,000
molecular weight cutoffs were used to separate free drug from
liposomal encapsulated drug. Each sample was diluted 10-fold
into acetate buffer (50 mM sodium acetate, 145 nM NaCl, pH
4.0) and 400 :L was transferred to the centrifugation device
and centrifuged for 18 min at 8100g (10,000 rpm). A centrifu-
gation time of 18 min and a speed of 8100g were chosen to
ensure that there was an adequate volume in the filtrate to
transfer to HPLC vials without risk of rupture to the mem-
branes because of a too high centrifugation force. These condi-
tions were previously shown to provide quantitative recovery.21
(Subsequently, it was found that centrifugation times of 10 min
were also effective when samples were further diluted by a fac-
tor of two.) The filtrate, representing the FCI component, was
analyzed by HPLC for ciprofloxacin content. The total amount
of ciprofloxacin, representing both the encapsulated and free
drug, was quantified by HPLC after diluting the CFI sample
20-fold into 80% methanol to solubilize the liposomes. The per-
cent encapsulation was determined by comparing the free drug
to the total drug in each sample.
In Vitro Release
The IVR assay measures the release of encapsulated
ciprofloxacin when incubated at 37◦C in 50% (v/v) bovine
serum.21 Briefly, the CFI samples were diluted to 50 :g/mL
ciprofloxacin in HEPES-buffered saline (HBS: 20 mM HEPES,
145 mMNaCl, pH 7.4) and mixed one-to-one with chilled (2◦C–
8◦C) bovine serum (Hyclone) and placed in a shakingwater bath
[Techne, TSBS40 (Staffordshire, UK)] at 37◦C and 150 rpm. Du-
plicate samples were removed after incubation for 30, 60, 120,
and 240min, diluted 1:1 with chilled (2◦C–8◦C)HBS and placed
in an ice-water bath to terminate any further release of encap-
sulated drug from the liposomes. The released ciprofloxacin
was separated from the liposome-encapsulated ciprofloxacin by
transferring 400 :L of each chilled sample to a Nanosep cen-
trifugal device and centrifuging at 8100g for 18 min. The fil-
trate was removed for subsequent quantitation of the released
ciprofloxacin by HPLC. This value was normalized by multiply-
ing by 1.05, to correct for a small but reproducible loss of free
drug in the filtration devices in the presence of serum.21 The
original CFI sample was diluted into 80% methanol to dissolve
the liposomes and allow for quantitation of the total amount of
ciprofloxacin by HPLC. The percent release at each time point
was calculated by comparing the free drug to the total drug.
Cryo-TEM
To obtain visual images of the liposome formulations, cryo-TEM
analysis was performed using a JEOL 2100 (Tokyo, Japan) in-
strument operated at 200 kV. The CFI samples were diluted to
approximately 5 mg/mL (10 mg/mL liposomes) with water and
3 :L of each sample was applied to a glow discharge Quantifoil
carbon grid (Jena, Germany) in a chamber controlled to 22◦C
and 100% relative humidity. Grids were blotted once with fil-
ter paper, at a blotting angle of 2 mm for 2 s, and vitrified by
plunging into liquid ethane using a Vitrobot (F.E.I., Eindhoven,
Netherlands). The vitrified samples were stored in liquid nitro-
gen prior to cryo-TEM analysis.
HPLC
The amount of ciprofloxacin in each sample was quantified us-
ing an HPLC method as described previously.22 Briefly, HPLC
analysis was performed using a Nucleosil C-18 column (5 :m,
4.6× 150mm2; Canadian Life Science (Peterborough, Ontario))
protected with a Nucleosil C-18 guard column (4 × 3.0 mm2;
Phenomenex (Torrance, California)) both at 35◦C. The mobile
phase was a mixture of 0.5% TEA in water, pH 3.0, and 100%
methanol (83:17, v/v), and the isocratic elution was performed
at a flow rate of 0.9 mL/min. Ciprofloxacin was detected and
quantified at a wavelength of 277 nm.
RESULTS
Liposomal Ciprofloxacin Encapsulation: Effect of Addition of
Polysorbate 20
Polysorbate 20 is present in a number of approved pharma-
ceutical products and so was chosen for initial evaluation be-
cause of the general knowledge about its suitability in inhaled
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formulations. When 50 mg/mL CFI was diluted with HB, and
increasing concentrations of polysorbate 20, up to 2.0%, were
added, there was a small concentration-dependent loss of en-
capsulated drug but the amount of free drug did not exceed
8% (Fig. 1a). The 30 and 10 mg/mL CFI samples decreased
to approximately 95% and 92% drug encapsulation, respec-
tively, at the highest polysorbate 20 concentration (i.e., 2%).
As expected, intermediate CFI concentrations, that is, 12.5, 15,
and 20 mg/mL, had encapsulation values which fell in between
those two curves.
For any given surfactant concentration, there was an in-
crease in drug release with decreasing CFI concentration, as
would be expected because the ratio of surfactant to liposomes
is greater. Therefore, one would expect more surfactant to be
associated with each individual liposome for the lower CFI con-
centration preparations and thus to have the potential for a
greater effect on drug release. At a constant ratio of surfactant
to liposomes, if no other changes were introduced, it might be
expected that the final encapsulation states would be compa-
rable. Although the individual data points were not selected to
keep the ratio of surfactant to liposomes constant, a comparison
can be made by following the dotted black lines in Figure 1a
for both a high and low ratio of surfactant to liposomes. In
both cases, there was a slight decrease in encapsulation with
decreasing CFI concentration over the concentration range of
30–10 mg/mL CFI, but the changes were modest (i.e., 1%–2%).
Liposomal Ciprofloxacin Encapsulation: Combination of Osmotic
Swelling and Polysorbate 20
In the previous experiment, we were unable to produce mean-
ingful increases in free drug, of more than 8%, even using a rel-
atively large amount of polysorbate 20 (i.e., 2%). The next series
of experiments were conducted to determine whether liposomes
subjected to osmotic swelling would be more responsive to the
addition of surfactant. In these experiments, CFI was diluted
with water, instead of HB, to create a hypotonic (hypoosmotic)
state. Polysorbate 20was added immediately after dilutionwith
water. In contrast to the previous studies for which there was
a minimal loss of encapsulated drug (Fig. 1a), the addition of a
surfactant in conjunctionwith osmotic swelling of the liposomes
resulted in a much greater loss of encapsulated drug, especially
for the lower CFI concentrations (Fig. 1b). The release of en-
capsulated drug happened very rapidly, well within 30 min,
and no further release was observed thereafter. The degree of
osmotic swelling would be expected to be the greatest for the
lowest CFI concentration preparations (i.e., 10 mg/mL) because
of the greater dilution of CFI and thus the largest reduction in
tonicity. And indeed those samples showed the greatest loss of
encapsulated drug. For the 10 mg/mL CFI preparation contain-
ing 2% polysorbate 20, the amount of released drug increased
from approximately 8% to >50% when the liposomes were di-
luted with water versus HB suggesting that osmotic swelling
acts synergisticallywith the addition of surfactant tomodify the
encapsulation state of the liposomes. The encapsulation state
of the highest concentration CFI preparation (i.e., 30 mg/mL),
across the range of polysorbate 20 concentrations, was no dif-
ferent when diluted with water or HB. This result suggests
that there may not have been sufficient osmotic swelling of the
30 mg/mL CFI preparations to have any effect on release of
encapsulated drug.
Congruous to the previous studies (Fig 1a), for any given
concentration of polysorbate 20, there was a greater extent
of release of encapsulated ciprofloxacin for more dilute CFI
formulations than for more concentrated CFI formulations
(Fig. 1b). In contrast to the previous studies, for which there
was little variation in encapsulation state across a constant ra-
tio of surfactant to liposomes (dotted lines in Fig. 1a), in these
studies there was a dramatic difference in encapsulation states
across a constant ratio of surfactant to liposomes (dotted lines
in Fig. 1b). For the 30mg/mLCFI formulation in 2%polysorbate
20, the encapsulation state was approximately 95%, whereas
it decreased to approximately 56% for 10 mg/mL CFI in 0.67%
polysorbate 20. Similarly, for the 30 mg/mL CFI formulation
in 0.8% polysorbate 20, the encapsulation state was again ap-
proximately 95%, whereas it decreased to approximately 67%
for 10 mg/mL CFI in 0.27% polysorbate 20. Although the ratio
of surfactant to liposomes remained constant along the dotted
lines in Figure 2B, the degree of tonicity, and hence the amount
of osmotic swelling, did not remain constant. The lower concen-
tration CFI preparations were more hypotonic and thus likely
experienced more osmotic swelling. This may explain why the
more dilute liposome solutions of CFI were more susceptible to
surfactant-induced release of encapsulated drug than for the
more concentrated solutions of CFI, at the same molar ratio of
surfactant to liposomes.
Liposomal Ciprofloxacin Encapsulation: Effect of Dilution Order
(Water and Polysorbate 20)
In a third experiment, the order of dilution was evaluated by
adding the surfactant to the 50 mg/mL CFI immediately af-
ter dilution with water, as was performed in the previous ex-
periments, or immediately before dilution with water. In this
experiment there was no meaningful difference in the encap-
sulation state between the two preparations across the range
of surfactant concentrations suggesting that order of dilution
is not critical to the final encapsulation state, at least as long
as the dilution steps are close together temporally (Fig. 1c).
Liposomal Ciprofloxacin Encapsulation: Effect of Equilibration
with Polysorbate 20 prior to Dilution with Water
In a fourth experiment, the encapsulation states of 30 mg/mL
CFI in a range of polysorbate 20 concentrations were measured
after 30 min equilibration, and then were remeasured after di-
lution with water to 10 mg/mL CFI (Fig. 1d). In contrast to the
previous experiment which suggested that the order of dilu-
tion did not have a significant impact on encapsulation state,
in this experiment, the final encapsulation state was very de-
pendent upon the dilution procedure. When the 10 mg/mL CFI
formulation was prepared directly from the 50 mg/mL CFI by
the addition of water and a surfactant, in either order (Fig. 1c),
there was a much greater decrease in encapsulation state ver-
sus when the 30 mg/mL CFI was allowed to equilibrate with
surfactant prior to dilution to 10 mg/mL (Fig. 1d). In the lat-
ter case, there was only a minimal change in the encapsula-
tion state upon the threefold dilution (Fig. 1d). This result
suggests that the final encapsulation state may be pathway
dependent (hence also time dependent) and predominantly ki-
netically based, rather than equilibrium based. In other words,
there may only be a transient time period for which the os-
motically swollen liposomes are susceptible to surfactant mod-
ification and if the surfactant has already equilibrated with
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the liposomes prior to osmotic swelling, as in this experiment,
subsequent osmotic swelling does not appear to enable the sur-
factants to associate in the same way to produce larger losses
of encapsulated drug.
Liposomal Ciprofloxacin Encapsulation: Applicable to Other
Surfactants?
To determine whether the surfactant-induced release of encap-
sulated ciprofloxacin in a hypoosmotic environmentwas specific
to polysorbate 20, or more broadly applicable to other closely re-
lated, nonionic surfactants, another series of experiments was
performedwith the following surfactants: polysorbate 80, Sp20,
Sp80, poloxamer L44, and poloxamer L62. Upon the addition
of a surfactant to CFI diluted with water to a final concentra-
tion of 12.5 mg/mL, all surfactants caused some release of en-
capsulated ciprofloxacin with the amount released increasing
with increasing surfactant concentration (Fig. 2a). However,
the amount of drug that was released was very dependent on
the choice of surfactant, with polysorbate 80 resulting in sub-
stantial release of ciprofloxacin, whereas none of the other non-
ionic surfactants that were tested produced more than 1%–2%
release of encapsulated drug over the surfactant concentration
ranges that were evaluated (Fig. 2a). At the same surfactant
concentrations, polysorbate 80 was more effective than polysor-
bate 20 (Fig. 2a vs. Fig. 1c) at causing greater release of encap-
sulated ciprofloxacin in the 12.5mg/mLCFI preparations.More
data points were not collected over the surfactant concentration
range studied because the focus of this experiment was to un-
derstand the general behavior of the surfactant interactions
with CFI, but not to fully map out the design space.
A follow-on experiment was conducted to more fully map out
the design space for polysorbate 80, and to determine how re-
producible this effect was for different manufactured batches
of CFI. The response of each of the three batches of CFI to
polysorbate 80 was comparable, with a large loss of 30%–35%
encapsulated drug for 0.1% polysorbate 80, and 40%–45% loss
of encapsulated drug for 0.2% polysorbate 20 (Fig. 2b). Higher
concentrations of polysorbate 20, up to 0.6%, did not signifi-
cantly alter the plateau value of approximately 45% released
drug (55% encapsulated drug).
Vesicle Size
The vesicle size of the various preparations was measured to
determine whether the addition of surfactant results in any
measurable change in liposome size. The mean vesicle size of
CFI was unchanged in the presence of either poloxamer L44
or poloxamer L62, increased by 1–3 nm for Sp20, Sp80, and
polysorbate 20, and increased by up to 8 nm for polysorbate 80
(Table 1).
IVR Profile
We have shown that addition of polysorbate 20 and polysorbate
80 surfactants to CFI, in a hypotonic environment, leads to
more extensive changes to the encapsulation state of the lipo-
somes than in the absence of osmotic swelling. We were also in-
terested whether the release properties of the liposomes could
be modified by surfactant addition. The IVR assay measures
the release of encapsulated ciprofloxacin from the liposomes
after incubation with bovine serum at 37◦C.21 Consistent with
the encapsulation assay data (Figs. 1b and 2a), the time zero
release values in the IVR assay (Fig. 3a) represent the state of
encapsulation before incubation with the release agent, that is,
the amount of “burst.” For the control CFI vial, the “burst” value
is approximately 1%. For DRCFI, which is a mixture of approx-
imately 70% CFI and 30% FCI solution, the “burst” value is
approximately 30%, as would be expected. For the 12.5 mg/mL
CFI containing various levels of surfactant, the amount of FCI,
or “burst,” increased with increasing polysorbate 20 from ap-
proximately 2% for 0.05% polysorbate 20 to approximately 27%
for 0.4% polysorbate 20 in the IVR assay (Fig. 3a).
The last time point in the IVR assay, at 4 h, represents the
complete extent of release of ciprofloxacin from the liposome
preparations. By the 4 h time point, all of the formulations
reached a plateau value in the IVR assay representing approx-
imately 100% release of encapsulated ciprofloxacin.
The IVR profiles for the CFI formulations containing 0.05,
and 0.1% polysorbate 20 were similar to that for CFI alone.
However, the IVR profile for the CFI formulation containing
0.4% polysorbate 20 had marked differences to that for CFI as
well as for DRCFI. The T30 min value is an approximate rep-
resentation of the “midpoint” of release for CFI.21 The T30 min
values increased with increasing polysorbate 20, from approx-
imately 44% for CFI alone to approximately 66% for CFI con-
taining 0.4% polysorbate 20. However, one cannot directly com-
pare the T30 min values of these formulations to assess changes
to the release rates because the encapsulation states were not
equivalent at the initial time point (T0 min). To address this is-
sue, one can “normalize” the T30 min values by subtracting the
initial value,T0 min, and dividing by the total available range for
release (T240 min – T0 min) and converting to a percentage: 100 ×
(T30 min − T0 min)/(T240 min − T0 min). The normalized T30 min val-
ues are 44.4% for CFI, and 43.4%, 46.8%, 47.6%, and 55.7%
for CFI containing 0.05%, 0.1%, 0.2%, and 0.4% polysorbate 20,
respectively. The encapsulated ciprofloxacin release rates were
relatively comparable, except for the CFI formulation contain-
ing 0.4% polysorbate 20. In addition, although CFI containing
0.4% polysorbate 20 had a comparable initial release value,
or “burst,” to that for DRCFI, 27% versus 30%, respectively,
its release rate was faster than DRCFI with a T30 min value
(un-normalized, as the initial values are similar) of 66% ver-
sus 57%, respectively. The normalized T30 min values of 55.7%
versus 41.6%, respectively, also demonstrate this difference in
release rates.
Polysorbate 80 had an even greater effect on the IVR profile
than polysorbate 20. CFI containing 0.2% polysorbate 80 had a
faster IVR profile than for CFI containing twice as much (0.4%)
polysorbate 20 (Figs. 3b vs. 3a). To investigate whether the
surfactant has altered the membrane permeability of the lipo-
somes and thus its release profile, or if the surfactant was sim-
ply operating as a release vehicle itself, control CFI was diluted
into the release vehicle (serum) with or without polysorbate 80
and the IVR assay was repeated (Fig. 3b). The concentration of
surfactant in the IVR assay in that experiment (0.0004%) was
identical to that for 12.5 mg/mL CFI containing 0.2% polysor-
bate 80 after the 500-fold dilution into the IVR assay buffer.
The presence of polysorbate 80 in the release buffer had no
effect on the IVR profile of CFI (Fig. 3b).
Cryo-TEM
To better understand the effect of the addition of polysorbate 20
on the structure and state of the liposomal ciprofloxacin vesi-
cles, 12.5 mg/mL CFI samples (diluted with water) with and
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Figure 2. (a) The effect of the addition of various surfactants on the state of ciprofloxacin encapsulation. CFI containing 50 mg/mL of encapsu-
lated ciprofloxacin was diluted to a final concentration of ∼12.5 mg/mL ciprofloxacin with water and an aliquot of 1% or 10% (w/v) surfactant to
achieve a final surfactant concentration of 0.01%, 0.05%, 0.1%, 0.5%, or 1.0% (w/v). The surfactants that were investigated included: poloxamer
L44, poloxamer L62, Sp20, Sp80, and polysorbate 80. After vortexing and allowing each sample to equilibrate for at least 30 min, the ciprofloxacin
encapsulation state was determined by centrifugal filtration in duplicate. Each data point represents the mean (n = 2). There are no data points
using 0.5% or 1% (w/v) Sp20 because of the poor miscibility of the solution at those concentrations. (b) The effect of the addition of polysorbate
80 on the state of ciprofloxacin encapsulation for three different batches of CFI. CFI containing ∼50 mg/mL of encapsulated ciprofloxacin was
diluted to a final concentration of ∼12.5 mg/mL ciprofloxacin with water and an aliquot of 1% (w/v) polysorbate 80 to achieve a final surfactant
concentration of 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, or 0.6% (w/v). After vortexing and allowing each sample to equilibrate for at least 30 min,
the ciprofloxacin encapsulation state was determined by centrifugal filtration.
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Table 1. The Vesicle Size Distribution for 12.5 mg/mL CFI in the Presence of the Following Surfactants: Poloxamer L44, Poloxamer L62,
Sp20, Sp80, Polysorbate 20, and Polysorbate 80
Surfactant (%) SPAN 80 SPAN 20 Pluronic L62 Polysorbate 80 Pluronic L44 Polysorbate 20
0 93.5 [26.0]
0.01 93.4 [26.0] 93.7 [27.6] 93.4 [27.6] 93.8 [29.0] 94.7 [34.8] 92.0 [30.6]
0.05 93.5 [26.5] 94.2 [28.9] 93.4 [26.5] 94.0 [24.9] 94.6 [30.4] 93.4 [30.8]
0.1 93.8 [28.2] 94.7 [29.9] 93.0 [25.2] 97.9 [29.2] 94.6 [30.3] 93.9 [30.7]
0.5 94.2 [34.0] NDa ND 101.3 [33.8] 94.7 [31.4] 95.2 [31.9]
1.0 96.7 [37.4] NDa 93.8 [24.0] 101.6 [26.9] 94.3 [34.0] 94.6 [27.4]
aPreparation did not form a miscible solution.
Vesicle size data are reported as the mean (in nm) and [SD].
ND, not done.
without various levels of polysorbate 20 were imaged by cryo-
TEM. The CFI formulation without surfactant was composed
of spherical, unilamellar liposomes between approximately 50
and 100 nm in size (Fig. 4a). The CFI liposomes do not appear to
form agglomerates in contrast to liposomes composed of choles-
terol and distearoyl PC, which are nonspherical and interact
attractively to form large clusters.12,23 CFI samples containing
0.05% polysorbate 20 (Fig. 4b), 0.2% polysorbate 20 (Fig. 4c),
and 0.4% polysorbate 20 (Fig. 4d) all appeared to be qualita-
tively similar to CFI with respect to liposome size and lamellar-
ity. However, with increasing concentration of polysorbate 20,
there were a greater proportion of liposomes that were lighter
in shading suggesting a loss of encapsulated ciprofloxacin
(Fig. 4d). There were also a very small fraction of disk-like
fragments, which may represent pieces of ruptured liposomes
(Fig. 4d). To determine whether the lighter density liposomes
are consistent with loss of encapsulated drug, empty liposomes
(Fig. 4e), and a 50:50mixture of empty liposomes and CFI, were
also imaged (Fig. 4f). The empty liposomes were comparable to
CFI in terms of size and lamellarity, but had lighter density
(Fig. 4e). The 1:1 mixture of the empty liposomes and CFI re-
vealed a mosaic of liposomes with both light and dark shading
in approximately equal proportion (Fig. 4f). These results sug-
gest that the addition of increasing amounts of polysorbate 20,
up to 0.4%, caused leakage of ciprofloxacin from a subset of
liposomes which retained their physical integrity after loss of
encapsulated drug.
DISCUSSION
We have investigated the interaction of surfactants with a
liposomal ciprofloxacin formulation with the goal to develop
novel formulations with modified encapsulation states and re-
lease properties. Our strategy was to use sublytic quantities
of surfactant, below the level that solubilizes the liposomes,
so that the liposome vesicles retain their integrity, but may
have altered drug release rates.15,16 The addition of polysor-
bate 20 resulted in a small loss of encapsulated drug when
mixed with CFI using isotonic HB as the dilution vehicle;
the amount of released drug increased with greater concen-
trations of surfactant, but even with 2% polysorbate 20 more
than 92% of the ciprofloxacin remained encapsulated (Fig. 1a).
These data are consistent with the established mechanism
that sublytic concentrations of surfactant form transient pores
in liposome bilayers allowing release of small quantities of
the encapsulated drug before the membrane barrier is fully
recovered.15,16
Liposomal ciprofloxacin preparations were also diluted with
water to create a hypotonic environment that would be ex-
pected to result in osmotic swelling of the liposomes.24–26 When
polysorbate 20 was added just prior to or just after dilution
with water, there was a much greater loss of encapsulated drug
suggesting a synergistic effect of osmotic swelling and surfac-
tant on release of encapsulated drug (Fig. 1c). The greater the
dilution of CFI with water, and thus the greater osmotic im-
balance between the interior and exterior of the liposomes, the
larger the loss of encapsulated ciprofloxacin. The combination
of osmotic swelling and 2% polysorbate 20 led to more than 50%
free drug for 10 mg/mL CFI (Fig. 1b) in contrast to only 8% free
drug in the absence of osmotic swelling (Fig. 1a).
The addition of polysorbate 20 (or polysorbate 80) causes
enhanced leakage of drug in a hypotonic liposome environ-
ment. But does it also alter the release rate of the drug that
remains encapsulated? For low concentrations of polysorbate
20, up to 0.2%, even in concert with osmotic swelling, there did
not appear to be a meaningful effect on the IVR release rate for
12.5 mg/mL CFI (Fig. 3a). This result suggests that osmotic
swelling of liposomes, when simultaneously exposed to low con-
centrations of surfactant, transiently allows enhanced release
of drug, but without long-term effect on the bilayer properties
that could alter drug release in the IVR assay. In contrast, for
higher concentrations of surfactant, for example, 0.4% polysor-
bate 20 or 0.2% polysorbate 20, there was a significant increase
in the IVR release rate for 12.5 mg/mL CFI (Figs. 3a and 3b).
This result is consistent with the increased bilayer permeabil-
ity model.5,11
In studies of surfactant interactions with liposomes and
phospholipid vesicles, turbidity measurements of the system
often increase with surfactant concentration as surfactant in-
creasingly becomes associated with the bilayers, and this has
been attributed to an increase in vesicle size.11,27 Once the vesi-
cles become saturated with surfactant, a decrease in turbidity
is often observed because of the partial solubilization of the bi-
layers and formation of mixed micelles which scatter less light.
Although no turbidity measurements weremade in our studies,
and our goal was to remain below the surfactant-solubilizing
concentration, we did observe a general trend of modest in-
creases of vesicle size with increasing surfactant for a number
of surfactants tested, consistent with this model (Table 1). The
increase in vesicle size was small for most surfactants but was
the greatest for polysorbate 80 with an increase in mean vesicle
size of up to 8 nm. This increase in vesicle size for polysorbate
80 is likely related to its structure and its propensity to be
more disruptive to the membrane bilayer. Although there may
be other explanations for this observation, the largest increase
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Figure 3. Evaluation of the effect of liposomal ciprofloxacin composition on the IVR assay. The in vitro release of 25 :g/mL ciprofloxacin in 50%
(v/v) bovine serum and 10 mM HEPES buffered saline, pH 7.4 after incubation at 37◦C for 4 h is reported. (a) IVR profiles for Control CFI (blue
diamonds), DRCFI (orange circles), 12.5 mg/mL CFI in 0.05% (w/v) polysorbate 20 (purple crosses), 12.5 mg/mL CFI in 0.1% (w/v) polysorbate
20 (green triangles), 12.5 mg/mL CFI in 0.2% (w/v) polysorbate 20 (blue stars), and 12.5 mg/mL CFI in 0.4% (w/v) polysorbate 20 (red squares).
Each value represents the mean (n = 2). (b) IVR profiles for Control CFI (blue diamonds), DRCFI (orange circles), 12.5 mg/mL CFI in 0.2% (w/v)
polysorbate 80 (red squares), and 12.5 mg/mL CFI in serum containing 0.0004% (w/v) polysorbate 20 (green stars). Each value represents the
mean (n = 2). Reprinted with permission from Ref. 21.
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Figure 4. Cryo-TEM micrographs of various preparations of liposo-
mal ciprofloxacin (CFI). The scale bar in the bottom left-hand corner
of each micrograph is 100 nm for a, b, e, and f and 200 nm for b and
c. All CFI samples were applied at a concentration of ∼10 mg/mL li-
posomes. (a) 12.5 mg/mL ciprofloxacin; (b) 12.5 mg/mL ciprofloxacin in
0.05% (w/v) polysorbate 20; (c) 12.5 mg/mL ciprofloxacin in 0.2% (w/v)
polysorbate 20; (d) 12.5 mg/mL ciprofloxacin in 0.4% (w/v) polysorbate
20; (e) empty liposomes; (f) 1:1 mixture of empty liposomes and CFI.
in vesicle size was also associated with the greatest loss in
encapsulated drug (Table 1) and the greatest effect on IVR re-
lease profile (Fig. 3b), which may reflect upon the extent of the
disruption and resulting size increase of the liposomes due to
the association with surfactant. It is noteworthy that in the
dynamic light scattering (DLS) studies, we did not observe a
second population of smaller particles, which would have been
consistent with the formation of surfactant micelles. It is pos-
sible that some micellar structures may have formed in these
studies, as DLS may have been insensitive to the presence of a
small percentage of micelles.
Polysorbate 80 had a more pronounced effect than polysor-
bate 20, both in terms of loss of drug encapsulation (Fig. 2a)
and increase in IVR rate (Fig. 3b). Although the head groups
are similar for both polysorbate surfactants, the hydrophobic
tail for polysorbate 80 is almost twice as long as for polysor-
bate 20 (C16 vs. C10) and has a kink in the middle, unlike
polysorbate 20 that has a saturated hydrophobic tail. Thus, the
tail of the polysorbate 80 surfactant will be more disruptive
upon insertion into the liposome bilayer than the polysorbate
20 tail, and explains the greater effect that polysorbate 80 has
on the transient release of encapsulated drug prior to adjust-
ment by the lipids and cholesterol in the membrane to a new,
more-compact state. Once the membrane has accommodated
the surfactant, there does not appear to be any further release
of encapsulated drug (data not shown). For low concentrations
of polysorbate 20, up to 0.2%, there did not appear to be much
effect on the IVR release rate of 12.5 mg/mL CFI suggesting
that the membrane permeability and packing were not too per-
turbed (Fig. 3a). However, the addition of 0.4% polysorbate 20
to 12.5 mg/mL CFI led to a more rapid release of encapsulated
drug in the IVR assay (Fig. 3a). For this formulation, the ratio
of surfactant to liposomes was 1:6.25 by weight, which suggests
that the surfactant could represent up to approximately 14%
of the liposome bilayer on average, if all of the surfactant was
incorporated into the liposomes. One possible explanation for
this transition is that once the surfactant reaches a critical
level (between 0.2% and 0.4% for polysorbate 20 and less than
0.2% for polysorbate 80 in 12.5 mg/mL CFI), the cholesterol
and lipids may be less able to accommodate the surfactant,
and while the membrane retains its barrier properties to en-
capsulated drug, it may be more easily fluidized after mixing
with serum in the IVR assay. The packing of cholesterol and
lipids around the polysorbate 80 tail will be even less effective
than for the polysorbate 20 tail, thus explaining the more pro-
nounced disruption to drug encapsulation and IVR profile at
lower surfactant concentrations for polysorbate 80.
To determine whether these observations are broadly appli-
cable to other nonionic surfactantswith similar chemistries, the
encapsulation studies were repeated using poloxamer L44 and
L62, and Sp20 and Sp80 surfactants. However, none of these
surfactants resulted in meaningful changes in the amount of
encapsulated drug. The Sp20 and Sp80 surfactants have iden-
tical hydrophobic tails to polysorbate 20 and polysorbate 80, re-
spectively, but a different head group. These surfactants were
much less disruptive than the polysorbates, indicating that the
specific hydrophilic head group plays a key role in this process.
For successful insertion of the surfactant tail into the bilayer,
the surfactant head group apparently must successfully as-
sociate with the hydrophilic head group of the phospholipid.
Both poloxamer surfactants, composed of a hydrophobic poly-
oxypropylene segment, flanked by two hydrophilic chains of
polyoxyethylene, had very little effect on drug encapsulation
(Fig. 2a), suggesting that they were also not effectively able to
insert into the liposome bilayer.
Cryo-TEM studies were conducted to shed light on the con-
sequences of the surfactant interactions with the liposomes.
That so much more drug is released under hypotonic condi-
tions raises the question of whether osmotic swelling is simply
enhancing the transient release of encapsulated drug after ex-
posure to surfactant, or if a large population of vesicles is being
completely disrupted. In other words, are a large fraction of li-
posomes releasing all of their drug payload, or are all liposomes
releasing some fraction of their payload, or is it a combina-
tion of the two. The cryo-TEM micrographs of mixtures of CFI
containing low levels of polysorbate 20 are practically indistin-
guishable from CFI alone (Figs. 4a–4c). All three micrographs
show predominantly spherical, unilamellar liposomes around
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50–100 nm in diameter. For these low levels of polysorbate 20
added to CFI in a hypotonic environment, there does not appear
to be meaningful changes in liposome size, shape, or integrity.
Micellar structures were not observed in any of the liposomal
samples with added surfactant.
When 0.4% polysorbate 20 was added to 12.5 mg/mL CFI in
a hypotonic environment, there was approximately 30% loss of
encapsulated drug. By cryo-TEM imaging, the majority of li-
posomes appeared unaltered in size and shape and there was
minimal liposomal debris which might be indicative of vesicle
rupture (Fig. 4d). However, a second population of liposomes
emerged, which were comparable in size, shape, and lamellar-
ity to the unmodified CFI liposomes, but had lighter shading
(Figs. 4d vs. 4a). These vesicles may have lost a substantial
fraction of their encapsulated drug, or all of it, as the density
of their interior space is not dissimilar to that for empty lipo-
somes (Figs. 4d–4f). This result suggests that a second release
mechanism may be occurring in the presence of higher concen-
trations of surfactant. Rather than simple leakage of a small
fraction of the drug content from some of the liposomes, a subset
of liposomes appear to have released all of their drug content
and yet retained their vesicular shape. Very little liposomal de-
bris or deformed liposomes were observed that might be indica-
tive of liposome rupture. This is consistent with a mechanism
that has been proposed that above a certain minimum surfac-
tant concentration, but below the solubilizing concentration,
the surfactant may cause an increase in the permeability of the
membranes without having any effect on their structure.5,11
However, that model does not explain why the majority of lipo-
somes appeared unaltered (Fig. 4d).
Although the use of surfactants to produce therapeutic nio-
somes has received much attention,28–30 there are few exam-
ples in the literature where surfactant was added to phospho-
lipid vesicles or liposomes to intentionally modify their physic-
ochemical properties or modulate drug release. In one study,
polysorbate 20, 60, or 80 was added to soy PC to produce unil-
amellar vesicles or multilamellar aggregates containing caf-
feine as the model drug.31 There was no sustained release of
caffeine from the unilamellar liposomes, whether or not surfac-
tant was present, as the release profiles were identical to that
for caffeine in solution.31 In contrast, in our study using unil-
amellar liposomes, although the presence of small amounts of
polysorbate 20 or 80 had a minimal effect on the release rate,
higher polysorbate concentrations, in combination with osmotic
swelling, caused a faster release profile in the IVR assay. An-
other key difference is that the surfactant was added to intact
liposomes in our study, whereas in the previous studies the
surfactant was added prior to liposome manufacture.
Although these studies on modifying the release rate of a
liposomal formulation speak to the promise of tailoring ther-
apy to an individual’s needs, there are many challenges that
would need to be addressed before this approach could be real-
ized in practice. The regulatory pathway for this new treatment
paradigm is unclear and so would require discussion and agree-
ment by the innovator with the Regulatory Agencies. As the
personalization involves relatively minor qualitative changes
in the formulation, and its primary purpose is to modulate the
PK profile with the view to optimize the treatment efficacy and
safety for each patient, this approach seems much easier to
regulate than introduction of products with fundamentally dif-
ferent compositions or manufacturing processes. Another hur-
dle would be how to determine the ideal release profile for each
patient. The answer clearly would depend upon the specific dis-
ease being addressed, the properties of the therapeutic being
delivered, and the characteristics of the patient that demanded
a personalized regimen. Finally, how would a clinical trial be
designed to demonstrate safety and efficacy when patients may
be receiving formulations with different release profiles? This
may not be a totally foreign concept. The active drug is the
same for each patient so it may be possible to apply a strat-
egy similar to those for drugs that are dosed on a mg/kg basis.
In those studies, the total amount of drug is individualized to
the patient, based on their body mass, so why not modify the
treatment based on other characteristics of a patient, like their
need for a shorter or longer release profile? In the case of the
liposomal ciprofloxacin formulation in this study, it is being de-
veloped as an aerosol therapy and has successfully completed
Phase 2 trials in noncystic fibrosis bronchiectasis patients colo-
nized with Pseudomonas aeruginosa.32 Onemight imagine that
if a sputum sample from a patient indicated colonization with
a bacterial strain with a higher minimum inhibitory concen-
tration, then the most effective treatment might be a faster
release profile resulting in higher ciprofloxacin concentrations
in the lung to better kill the more resistant pathogen. The clin-
ical trial design and its safety and efficacy endpoints may not
be much changed from the standard situation when the formu-
lation is not individualized to the patient.
CONCLUSIONS
We have demonstrated that the encapsulation state and IVR
properties of a liposomal ciprofloxacin formulation (CFI) could
be modified by the addition of polysorbate surfactant to the
formed liposomes. Moreover, the effect of surfactant was signif-
icantly enhanced if the liposomes were exposed to a hypotonic
environment, to induce osmotic swelling, at the time of surfac-
tant addition. Osmotic swelling alone, in the absence of sur-
factant addition, did not cause significant loss of encapsulated
drug or a change in the IVR properties (data not shown). In the
case for 12.5 mg/mL CFI containing 0.4% (w/v) polysorbate 20,
or 0.2% (w/v) polysorbate 80, the encapsulation state was re-
duced from >99% to approximately 70%. The 12.5 mg/mL CFI
preparation containing 0.4% (w/v) polysorbate 20, or 0.2% (w/v)
polysorbate 80, also had altered IVR properties, with faster
rates of drug release, suggesting that the permeability of the
bilayer was also affected. These studies suggest that it may one
day be possible to tailor therapy to an individual, by dialing
in the desired encapsulation state and release rate of a liposo-
mal formulation by simple addition of an aliquot of a selected
surfactant, at a specific surfactant concentration, to the liposo-
mal drug product. These studies may form the basis for a new
paradigm of modifying the release profiles of a liposome formu-
lation by the end user, to better meet their specific treatment
needs.
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